

Table S3 Characteristics of patients participating in the survey and satisfaction level with MTX pens currently available on the market

| | Rheumatoid Arthritis (n=92) | | | Moderate or Severe Psoriasis (n=88) | | |
|---|--------------------------------|--------------|--------------|--|--------------|--------------|
| Country | D (n=32) | F (n=30) | UK (n=30) | D (n=30) | F (n=30) | UK (n=28) |
| Females | 16 (50%) | 15 (50%) | 19 (63%) | 18 (60%) | 15 (50%) | 17 (61%) |
| Age | | | | | | |
| < 40 years | 8 (25%) | 14 (47%) | 12 (40%) | 7 (23%) | 14 (47%) | 14 (50%) |
| 40 – 59 years | 16 (50%) | 12 (40%) | 11 (37%) | 19 (63%) | 13 (43%) | 8 (29%) |
| ≥ 60 years | 8 (25%) | 4 (13%) | 7 (23%) | 4 (13%) | 3 (10%) | 6 (21%) |
| Type of device used: | | | | | | |
| metoject®/metex® PEN | 24 (75%) | 15 (50%) | 17 (57%) | 20 (67%) | 12 (40%) | 11 (39%) |
| Nordimet® pre-filled pen | 14 (44%) | 17 (57%) | 15 (50%) | 14 (47%) | 18 (60%) | 16 (57%) |
| Methofill® pre-filled injector | 0 | 5 (17%) | 3 (10%) | 0 | 9 (30%) | 6 (21%) |
| Self-injection | | | | | | |
| Always | 30 (94%) | 19 (63%) | 26 (87%) | 24 (80%) | 21 (70%) | 23 (82%) |
| Mostly | 2 (6%) | 11 (37%) | 4 (13%) | 6 (20%) | 9 (30%) | 5 (18%) |
| Duration of using a device ^a | | | | | | |
| > 3 months but up to 6 months | 0 | 0 | 0 | 7 (23%) | 1 (3%) | 5 (18%) |
| > 6 months | 32 (100%) | 30 (100%) | 30 (100%) | 23 (77%) | 29 (97%) | 23 (82%) |
| Satisfaction level | | | | | | |
| Average ± SD | 8.8 ± 1.5 | 8.1 ± 1.5 | 7.9 ± 2.1 | 7.9 ± 1.7 | 7.6 ± 2.3 | 7.7 ± 1.7 |
| Number of responses with | | | | | | |
| low satisfaction level (1 or 2) | 0 (0%) | 0 | 0 | 0 | 2 (7%) | 0 |
| top satisfaction level (9 or 10) | 20 (63%) | 11 (37%) | 15 (50%) | 10 (33%) | 11 (37%) | 9 (32%) |

Notes: ^a Duration of using a pen influenced by inclusion criteria (see method section)

Abbreviations: D, Germany; F, France; UK, United Kingdom; SD, standard deviation